79/100 B+ · Low risk
No major risk flags in the public sources we cover Indicative TraceComp estimate from public sources — an automated indicator, not a credit decision, a completed due-diligence check, or a guarantee. Verify against the official register.

ℹ️ No matches surfaced in the limited public sources we cover (sanctions, screening, insolvency, control). This is an automated indicator — not an exhaustive check, a credit decision, or a guarantee, and absence of a match does not mean none exists. Verify against the official register.

Think this is wrong? This is an automated estimate — request a human review or correction.

CROSSJECT PHARMA

Active Simplified joint-stock company (SAS) Pharmaceuticals Active for 9 years

Simplified joint-stock company (SAS) · RC 822999611 · Active since 2016

B+

Overview

CROSSJECT PHARMA is a simplified joint-stock company (sas) registered in France, since 2016. The company operates in the pharmaceuticals sector. Its TraceComp score of 79 (B+) indicates solid fundamentals and low apparent risk.

Company Information

Registration Number
822999611
Legal Form
Simplified joint-stock company (SAS)
Registered
2016-10-05

Financial Profile

Latest filed accounts: FY 2017 · most recent available in public filings

Revenue (2017) —
Net Income -4,767 EUR
Total Assets 101,032 EUR
Altman Z 3.27 safe

Multi-year financials & ratios

1 year of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Research Output

Active research organization. 13 publications · 126 citations · h-index 6 in the global scholarly record (OpenAlex — 82.9M papers). Top fields by publication volume: Computer Science (35%) · Agricultural and Biological Sciences (20%) · Medicine (15%).

See full research profile — top researchers & publications →

Source: OpenAlex (CC0). Objective publication & citation counts.

Patent Portfolio

Active patent holder. 43 patents · 20 active · 43 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Risk Signals

No adverse legal events have been recorded for this company.

  • Net loss reported in FY 2017
  • Altman Z-Score in the safe zone

Data Sources & Freshness

Data sourced from: bulk register.